Moreover, the effective use of other molecular targeted therapeutic drugs, such as epithelial growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) for cases with EGFR gene mutation [15], anaplastic lymphoma kinase (ALK)-TKI for ALK fusion gene-positive cases [16], or immunity checkpoint inhibitors (ICI) for cases with high expression of programmed cell death ligand 1 case in PPC [17, 18] is expected to improve the treatment strategy for PPC. This evidence concerns the gene EGFR and primary peritoneal carcinoma.